Retrospective cohort study shows pomalidomide impacts mobilization outcomes in multiple myeloma patients, suggesting tailored strategies may be needed.
Key Points
Evaluate the effect of pomalidomide-containing induction on hematopoietic stem cell mobilization in multiple myeloma patients.
Retrospective cohort study of TE-NDMM patients from Jan–Nov 2024.
Patients categorized into POM-exposed and non-POM groups.
Analyzed poor mobilizer incidence, CD34+ yield, and apheresis sessions.
Higher poor mobilizer incidence in POM group (27.3%) vs non-POM group (17.6%), p=0.31.
Median CD34+ yield comparable between groups (5.2 vs 5.6 million/kg).
Increased plerixafor use trend in POM group (45.5% vs 33.3%), p=0.28.